{Reference Type}: Journal Article
{Title}: The treatment and survival of patients with postoperative recurrent thymic carcinoma and neuroendocrine carcinoma: a multicenter retrospective study.
{Author}: Miyata R;Hamaji M;Omasa M;Miyahara S;Aoyama A;Takahashi Y;Sumitomo R;Huang CL;Hijiya K;Nakagawa T;Yokoyama Y;Kawakami K;Sonobe M;Ikeda M;Fujinaga T;Suga M;Hirota S;Kojima F;Bando T;Takahashi M;Terada Y;Shoji T;Katakura H;Muranishi Y;Miyahara R;Date H;
{Journal}: Surg Today
{Volume}: 51
{Issue}: 4
{Year}: Apr 2021
{Factor}: 2.54
{DOI}: 10.1007/s00595-020-02102-7
{Abstract}: OBJECTIVE: There are few data available on the outcomes of postoperative recurrent thymic carcinoma (TC) and thymic neuroendocrine carcinoma (TNEC). The aim of this study is to evaluate the treatment and survival in patients with recurrent TC and TNEC after undergoing surgical resection.
METHODS: A retrospective chart review was performed using our multicenter database to identify patients with a postoperative recurrence of TC and TNEC from 1995 to 2018. The clinicopathological factors were reviewed and the survival outcomes were analyzed.
RESULTS: Sixty patients were identified among 152 patients who underwent resection of TC and TNEC. The median follow-up period from the first recurrence was 14.8 months (range 0-144). The 5-year post-recurrence survival was 23% for the whole cohort. According to a univariable analysis, advanced stage [hazard ratio (HR) 2.81, 95% confidence interval (CI) 1.09-9.54], interval between primary surgery and recurrence (HR 0.97, 95% CI 0.95-0.99), any treatment for recurrence (HR: 0.27, 95% CI 0.13-0.58) and chemotherapy for recurrence (HR: 0.46, 95% CI 0.22-0.95) were significant factors related to post-recurrence survival.
CONCLUSIONS: Chemotherapy rather than surgery appears to be the mainstay treatment for managing patients with postoperative recurrent TC and TNEC and it may also be considered in multidisciplinary management. Further studies with a larger sample size are required to confirm our findings.